The Company is developing Teverelix® as a best-in-class market product for advanced prostate cancer patients with high CV risk and a first in class product for Acute Urinary Retention Relapse ...

The phase 2b study is an open-label trial that will enroll 40 men with advanced prostate cancer who are appropriate candidates for ADT. Participants will receive an initial loading dose of teverelix ...

Relugolix and degarelix are both effective in achieving and maintaining sustained castration in advanced prostate cancer. Relugolix’s oral form provides convenience, eliminating the need for frequent ...

Camcevi ETM contains 21mg of leuprolide and is administered every 3 months. The Food and Drug Administration (FDA) has approved Camcevi ETM ®, a long-acting formulation of leuprolide mesylate, for the ...

A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor growth and slow symptom advance. File Photo by Billie Jean Shaw/UPI A new ...

Advanced prostate cancer treatment requires a personalized approach, considering disease stage, comorbidities, and patient preferences. ARPIs have revolutionized treatment, highlighting the need for ...

Prostate cancer diagnoses increased by 3% per year from 2014 to 2021, with the sharpest increase seen in advanced-stage disease. Prostate cancer mortality rates have continued to decline, but at a ...

For the first time ever, NTNU researchers have identified new characteristics of aggressive prostate cancer. The research ...

(BPT) – This content is sponsored and provided by Myovant Sciences and Pfizer Inc. After retiring, Mike settled into Arlington, Virginia, right outside of Washington, D.C., where he was a teacher for ...